PROGEN logo

Prostatype Genomics AB (publ) Stock Price

OM:PROGEN Community·SEK 35.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

PROGEN Share Price Performance

SEK 0.60
-7.45 (-92.55%)
SEK 0.60
-7.45 (-92.55%)
Price SEK 0.60

PROGEN Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

6 Risks
0 Rewards

Prostatype Genomics AB (publ) Key Details

SEK 715.0k

Revenue

SEK 21.8m

Cost of Revenue

-SEK 21.1m

Gross Profit

SEK 24.2m

Other Expenses

-SEK 45.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Feb 12, 2026
-0.77
-2,948.25%
-6,336.50%
0%
View Full Analysis

About PROGEN

Founded
2007
Employees
6
CEO
Fredrik Rickman
WebsiteView website
www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

Recent PROGEN News & Updates

Recent updates

No updates